Comparison of extrafine and non-extrafine inhaled corticosteroids/long-acting ?2-agonists as ...

1. Porsbjerg C, Melén E, Lehtimäki L, Shaw D. Asthma. Lancet 2023;401:858–873.
crossref pmid
2. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003;139(5 Pt 1):359–370.
crossref pmid pdf
3. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res 2010;690:24–39.
crossref pmid pmc
4. Meltzer EO, Kuna P, Nolte H, Nayak AS, Laforce C, P04073 Study Investigators. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur Respir J 2012;39:279–289.
crossref pmid
5. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405–1411.
crossref pmid
6. Usmani OS, Singh D, Spinola M, Bizzi A, Barnes PJ. The prevalence of small airways disease in adult asthma: a systematic literature review. Respir Med 2016;116:19–27.
crossref pmid
7. Scichilone N, Contoli M, Paleari D, et al. Assessing and accessing the small airways; implications for asthma management. Pulm Pharmacol Ther 2013;26:172–179.
crossref pmid
8. Usmani OS. Small airways dysfunction in asthma: evaluation and management to improve asthma control. Allergy Asthma Immunol Res 2014;6:376–388.
crossref pmid pmc
9. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009;124(6 Suppl):S88–S93.
crossref pmid
10. Nam TH, Kang SY, Lee SM, Kim TB, Lee SP. Comparison of two pMDIs in adult asthmatics: a randomized double-blind double-dummy clinical trial. Tuberc Respir Dis (Seoul) 2022;85:25–36.
crossref pmid pdf
12. Kanniess F, Scuri M, Vezzoli S, Francisco C, Petruzzelli S. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler®) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: a randomised, double-blind trial. Pulm Pharmacol Ther 2015;30:121–127.
crossref pmid
13. Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007;61:1874–1883.
crossref pmid
14. Kim SH, Kim TB, Kim SH, et al. Real-life clinical use of Symbicort ® maintenance and reliever therapy for asthmatic patients in Korea. Allergy Asthma Immunol Res 2018;10:88–94.
crossref pmid pdf
15. Carr TF, Altisheh R, Zitt M. Small airways disease and severe asthma. World Allergy Organ J 2017;10:20.
crossref pmid pmc pdf
16. Cohen J, Postma DS, Douma WR, Vonk JM, De Boer AH, ten Hacken NH. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur Respir J 2011;37:532–540.
crossref pmid
17. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100:375–384.
crossref pmid
18. Leach C. Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999;104:S250–S252.
crossref pmid
19. Benfante A, Basile M, Battaglia S, Spatafora M, Scichilone N. The use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics. Ther Clin Risk Manag 2016;12:1553–1562.
crossref pmid pmc pdf
20. Lavorini F, Pedersen S, Usmani OS, Aerosol Drug Management Improvement Team (ADMIT). Dilemmas, confusion, and misconceptions related to small airways directed therapy. Chest 2017;151:1345–1355.
crossref pmid
21. Papi A, Mansur AH, Pertseva T, et al. Long-term fluticasone propionate/formoterol fumarate combination therapy is associated with a low incidence of severe asthma exacerbations. J Aerosol Med Pulm Drug Deliv 2016;29:346–361.
crossref pmid pmc
22. El Baou C, Di Santostefano RL, Alfonso-Cristancho R, et al. Effect of inhaled corticosteroid particle size on asthma efficacy and safety outcomes: a systematic literature review and meta-analysis. BMC Pulm Med 2017;17:31.
pmid pmc
23. Nicolini G, Scichilone N, Bizzi A, Papi A, Fabbri LM. Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations. Ther Clin Risk Manag 2008;4:855–864.
pmid pmc
24. de Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Can ‘extrafine’ dry powder aerosols improve lung deposition? Eur J Pharm Biopharm 2015;96:143–151.
crossref pmid
25. Haughney J, Price D, Barnes NC, Virchow JC, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104:1237–1245.
crossref pmid
26. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588–599.
crossref pmid pmc pdf
27. Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev 2006;58:996–1008.
crossref pmid
28. Alfieri V, Aiello M, Pisi R, et al. Small airway dysfunction is associated to excessive bronchoconstriction in asthmatic patients. Respir Res 2014;15:86.
crossref pmid pmc pdf
29. Papi A, Corradi M, Pigeon-Francisco C, et al. Beclometasone- formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013;1:23–31.
crossref pmid
30. Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246–256.
crossref pmid
31. Braido F, Arnaboldi E, Barile S, et al. BDP/FF NEXThaler to improve asthma control status in the real world: the NEWTON study. J Asthma Allergy 2023;16:1177–1186.
crossref pmid pmc pdf
32. Dębowski T, Marko M, Rogala B, Majak P, Pawliczak R. Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy - CONTROL study. Pulm Pharmacol Ther 2024;84:102272.
crossref pmid
33. Ställberg B, Naya I, Ekelund J, Eckerwall G. Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. Int J Clin Pharmacol Ther 2015;53:447–455.
crossref pmid pmc
34. Warren S, Taylor G, Smith J, Buck H, Parry-Billings M. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique. J Aerosol Med 2002;15:15–25.
crossref pmid
35. Corradi M, Chrystyn H, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv 2014;11:1497–1506.
crossref pmid
36. Quanjer PH, Weiner DJ, Pretto JJ, Brazzale DJ, Boros PW. Measurement of FEF25–75% and FEF75% does not contribute to clinical decision making. Eur Respir J 2014;43:1051–1058.
crossref pmid
37. Stanojevic S, Wade A, Stocks J, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med 2008;177:253–260.
crossref pmid
38. Postma DS, Brightling C, Baldi S, et al.; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med 2019;7:402–416.
crossref pmid
39. van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013;131:646–657.
crossref pmid
40. Pizzichini E, Brusselle G, Edwards D, et al. Run-in periods and treatment outcomes in asthma trials: a narrative review. Contemp Clin Trials Commun 2024;42:101382.
crossref pmid pmc

Comments (0)

No login
gif